Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published 14 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The food segment is expected to exceed its full-year plan by ¥16.0 billion, while the pharmaceutical segment is expected to fall ¥2.8 billion short, resulting in full-year consolidated revenue being expected to exceed the forecast announced on 14 May 2026. Profit forecasts were left unchanged because the effects of foreign exchange rates and raw material costs need to be assessed carefully.
Total extraordinary losses for the interim period were ¥3,705 million, comprising ¥1,062 million in losses on disposal of fixed assets, ¥456 million in losses on reduction of fixed asset costs, ¥1,111 million in impairment losses, ¥909 million in losses from business restructuring and ¥166 million in other losses. In addition, a ¥3.1 billion loss on the transfer of 日本罐詰株式会社 is expected as a subsequent event.
| Item | Details |
|---|---|
| Net Sales | ¥1,212,000 million → ¥1,225,000 million（+1.1%） |
| Operating profit | ¥100,000 million → ¥100,000 million |
| Ordinary income | ¥101,000 million → ¥101,000 million |
| Profit attributable to owners of the parent | ¥62,500 million → ¥62,500 million |
| Net income per share | ¥230.61 / sen → ¥230.61 / sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | 14 May 2026 |
| Previous-period results | Fiscal year ended March 2026: Revenue ¥1,173,688 million, operating profit ¥93,307 million, ordinary profit ¥96,571 million, profit attributable to owners of the parent ¥35,076 million, basic earnings per share ¥129.42 |
| Reason for the revision | The food segment is expected to exceed its full-year plan by ¥16.0 billion, while the pharmaceutical segment is expected to fall ¥2.8 billion short, resulting in full-year consolidated revenue being expected to exceed the forecast announced on 14 May 2026. Profit forecasts were left unchanged because the effects of foreign exchange rates and raw material costs need to be assessed carefully. |
| Details and amount of extraordinary loss | Total extraordinary losses for the interim period were ¥3,705 million, comprising ¥1,062 million in losses on disposal of fixed assets, ¥456 million in losses on reduction of fixed asset costs, ¥1,111 million in impairment losses, ¥909 million in losses from business restructuring and ¥166 million in other losses. In addition, a ¥3.1 billion loss on the transfer of 日本罐詰株式会社 is expected as a subsequent event. |
| Dividend forecast revision | No change (whether the dividend forecast has been revised from the most recently announced forecast: No) |
| Consolidated / non-consolidated | Consolidated |
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the food segment, nutrition and feed businesses are expected to exceed plan, while the food solutions business is expected to fall short, resulting in the segment as a whole exceeding the full-year plan by ¥16.0 billion. The pharmaceutical segment is expected to fall ¥2.8 billion short of its full-year plan, mainly due to the overseas business, but the full-year revenue forecast was revised because total revenue is expected to exceed the forecast announced on 14 May 2026. Profit forecasts were left unchanged because the effects of foreign exchange rates and raw material costs need to be assessed carefully.